Treatment habits and weight changes before and after tirzepatide price rise in over one million UK adults paying for their own obesity care

A significant price increase of up to 170% for tirzepatide is anticipated in September 2025.

• Glucagon-like peptide-1 (GLP-1) receptor agonist-based medicines show effectiveness in managing overweight and obesity.
• Real-world evidence on these treatments is currently limited, particularly in self-funded healthcare settings.
• The study focuses on treatment patterns and provider reach within a large UK telehealth provider.
• Changes in treatment choices may occur due to the impending price increase of tirzepatide.
• Longitudinal weight trajectories are being estimated to understand the impact of these treatments over time.

Simplified